Familial Hypercholesterolemia (FH)
High-intensity lipid-lowering strategy for suspected or confirmed familial hypercholesterolemia, with genetics referral, cascade evaluation, and early advanced-therapy authorization.
Presentation
The clinical presentation raises meaningful concern for familial hypercholesterolemia, particularly in light of an LDL cholesterol concentration approaching or exceeding 190 mg/dL, a family history of premature coronary artery disease, inherited dyslipidemia, and additional cardiovascular risk indicators.
Referral to a genetics professional for counseling and consideration of molecular testing may be beneficial for confirmation of FH, individualized treatment planning, and cascade evaluation of biologically related family members.
High-intensity lipid lowering
A high-intensity lipid-lowering strategy may be appropriate. Rosuvastatin 20 mg by mouth once daily may be initiated, followed by dose advancement according to individual tolerability while pursuing recommended LDL cholesterol targets.
LDL cholesterol objectives in FH
For adults receiving primary prevention without a confirmed diagnosis of FH, an LDL cholesterol objective below 100 mg/dL may be appropriate.
Once heterozygous familial hypercholesterolemia has been established, an LDL cholesterol goal below 70 mg/dL may be reasonable for primary prevention.
If both FH and established clinical atherosclerotic cardiovascular disease are present, consideration should be given to intensifying therapy toward an LDL cholesterol level below 55 mg/dL, consistent with contemporary lipid-management recommendations.
Formal diagnostic assessment
Because the degree of LDL elevation is compatible with possible FH, formal assessment using validated diagnostic instruments, including the Dutch Lipid Clinic Network Criteria, may assist in establishing diagnostic certainty and guiding subsequent management.
Advanced therapy authorization
Early preparation of insurance authorization materials for additional lipid-lowering treatment may be worthwhile, particularly if LDL cholesterol remains substantially elevated despite maximally tolerated statin therapy or if FH is confirmed.
Potential therapeutic options include PCSK9 inhibitors such as Repatha or Praluent, together with bempedoic acid-containing therapies including Nexletol or Nexlizet.
Initiating the authorization process before a final treatment decision may help reduce delays should combination therapy become clinically indicated.